Global Liver Disease Diagnostics Market is valued approximately at USD 29.3 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 6.5% over the forecast period 2020-2027. Liver Disease Diagnostics is the detecting of the cause and extent of liver disease and it further includes the treatment process. It consists of blood tests, imaging tests, checking a tissue sample, treatment method and clinical trials. Factors such as growing geriatric population and rising prevalence of acute and chronic liver diseases will increase the demand for liver disease diagnostic market. For instance, according to the World Health Organization (WHO), the total new cases of liver cancer that were reported in 2018 were 841,080 and an estimated 781, 631 people died due to liver cancer, globally. Moreover, increasing incidences of end stage liver failure due to rising heavy alcohol consumption, growing prevalence of obesity and the metabolic syndrome are some of the major factors which can upsurge the growth of global organ care system for liver. For instance: According to Statista, alcohol consumption in India was 5.4 billion liters in 2016 and is estimated to reach about 6.5 billion liters by 2020. Also, as per Summary Health Statistics, the number of U.S. adults diagnosed with any sort of liver disease was 3.27 million in 2013 and which rose to 4.5 million adults in 2018. However, the stringent government regulations, high cost incurred in drug R&D and side effects associated with medication are some factors restraining the growth of global Liver Disease Diagnostics market during the forecast period.

The regional analysis of global Liver Disease Diagnostics market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the the fast adoption of new technology, high investments in R&D and presence of key players are some factors expected to be responsible for the growth of the market for liver disease diagnostics in the region. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2027.

Major market player included in this report are:
Abbott Laboratories
F. Hoffmann-La Roche AG
Randox Laboratories
Boston Scientific Corporation
Siemens Healthineers AG
BioMerieux
Quest Diagnostics
Biosino Bio-technology
Horiba, Ltd.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Diagnosis Technique:
Laboratory Tests
Imaging
Endoscopy
Biopsy
Others

By End-Use:
Hospitals
Laboratories
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2017, 2018
Base year - 2019
Forecast period - 2020 to 2027

Target Audience of the Global Liver Disease Diagnostics Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors